GE HealthCare is a large medical technology company that makes imaging equipment, patient monitoring devices, and pharmaceutical diagnostics products. The company spun off from GE in January 2023. Its core imaging products — CT scanners, MRI systems, X-ray machines, ultrasound systems, and nuclear medicine (PET/SPECT) systems — are sold as capital equipment to hospitals, health systems, imaging centers, and academic institutions in over 160 countries. GE HealthCare's pharmaceutical diagnostics (PDx) business supplies the contrast agents and radiopharmaceuticals that make imaging scans more informative; this is a recurring, consumable-like revenue stream that grows with procedure volumes. After equipment is installed, GE HealthCare provides maintenance, repair, and software upgrade contracts, which are recurring and high-margin. In total, roughly 45%+ of revenues are recurring. The company organizes its business into four segments: Imaging (CT, MRI, X-ray, molecular imaging), Advanced Visualization Solutions (ultrasound and image-guided therapy), Patient Care Solutions (monitoring, cardiology, anesthesia), and PDx. GE HealthCare's growth strategy centers on combining imaging hardware, proprietary radiopharmaceuticals, and AI software into integrated disease-state solutions — most visibly in nuclear cardiology, where GE HealthCare makes the PET scanner, supplies the radiotracer Flyrcado, and provides AI interpretation tools. The company supplements organic growth with tuck-in acquisitions in digital health, AI, and radiopharmaceuticals.